Drug-induced injury: A topic to bear in mind;Atteintes hepatiques medicamenteuses, il faut y penser!

Schweizerische Medizinische Wochenschrift

Volumn 126, Issue 48, 1996, Pages 2094-2096

  Kondo Oestreicher, M ^a,c   Desmeules, J ^a   Giostra, E ^a   Gross, B ^b   Hadengue, A ^a   Dayer, P ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b Office Intercantonal de Contrôle des Médicaments   (Switzerland)

^c Hôpital Cantonal   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMOXICILLIN PLUS CLAVULANIC ACID; ANALGESIC AGENT; ANTIBIOTIC AGENT; BUTYROPHENONE DERIVATIVE; CAPTOPRIL; CARBAMAZEPINE; CARDIOVASCULAR AGENT; COUMARIN DERIVATIVE; CYCLOSPORIN A; DICLOFENAC; ENALAPRIL; GASTROINTESTINAL AGENT; GLIBORNURIDE; ISONIAZID; METHOTREXATE; MIANSERIN; OMEPRAZOLE; ORAL ANTIDIABETIC AGENT; PROPYLTHIOURACIL; PSYCHOTROPIC AGENT; RANITIDINE; TERFENADINE;

CONFERENCE PAPER; HUMAN; IATROGENIC DISEASE; LIVER INJURY; LIVER TOXICITY; MAJOR CLINICAL STUDY; ADULT; AGED; ARTICLE; COMORBIDITY; DRUG MONITORING; DRUG THERAPY; FEMALE; MALE; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; SWITZERLAND; TOXIC HEPATITIS;

ADULT; AGED; COMORBIDITY; DRUG MONITORING; DRUG THERAPY; FEMALE; HEPATITIS, TOXIC; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SWITZERLAND;

EID: 0029849474     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Døssing M, Sonne J: Drug-induced hepatic disorders, incidence, management and avoidance. Drug Safety 1993; 9: 441-449.
2. Bakke OM, Manocchia M, de Abajo M, Kaitin KI, Lasagna L: Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther 1995; 58: 108-117.
3. Borel S, Vogt N, Stoller R, Dayer P: Atteintes hépatiques médicamenteuses: médicaments en cause et facteurs de risque. Schweiz Med Wochenschr 1995; 125 (Suppl. 69): 73.
4. Benhamou JP: Métabolisme hépatique des médicaments et lésions hépatiques médicamenteuses. Médecine/Sciences 1986; 2: 356-357.
5. Bernuau J, Benhamou JP: Fulminant and subfulminant liver failure. In: McIntyre N, Benhamou JP, Bircher J, Rizzetto M, Rodes J (éd): Oxford textbook of clinical hepatology. Oxford: Oxford University Press, 1991: 923-942.
6. Sherlock S: The spectrum of hepatotoxicity due to drugs. Lancet 1986; 2: 440-444.
7. Schiano TD, Black M: New developments in drug hepatotoxicity. Curr Opinion Gastroenterol, Curr Sci 1995; 11: 267-273.
8. e éd. Amsterdam: Elsevier, 1992.
9. Zimmermann HJ, Ishak K: General aspects of drug induced liver disease. In: Cullen H, Lewis JH (éd): Drug-induced liver disease. Gastroenterol Clin North Am 1995; 24: 739-757.
10. Ishak KG, Zimmermann HJ: Morphologic spectrum of drug-induced hepatic disease. In: Cullen H, Lewis JH (éd): Drug-induced liver disease. Gastroenterol Clin North Am 1995; 24: 759-786.
11. Lee WM: Drug-induced hepatotoxicity. N Engl J Med 1995; 333: 1118-1127.
12. c révision. Genève: OMS, 1977.
13. c révision, Genève: OMS, 1993.
14. Edwards IR, Biriell C: Harmonisation in Pharmacovigilance. Drug Safety 1994; 10: 93-102.
15. Danan G: Définitions et critères d'imputation des atteintes hépatiques aiguës médicamenteuses: conclusions d'une réunion internationale de consensus. Gastroenterologie Clin Biol 1993; 17: H17-H21.